Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary Deposition of Breztri Aerosphere in COPD
NCT03906045Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoint: Percentage of emitted dose deposited in the lungs at Day 1. Started Apr 2019; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03906045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906045.